HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01847248

Enrollment

118

Registered

2013-05-06

Start date

2011-05-31

Completion date

2013-10-31

Last updated

2013-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis, biomarker, HSPA12B

Brief summary

* Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis. * HSPA12B is primarily located in endothelial cells and detectable during sepsis. * The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adult patients * Patients meet the diagnostic criteria according to the grouping

Exclusion criteria

* patients without informed consent * patients who were undergoing continuous renal replacement therapy before sampling * patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on

Design outcomes

Primary

Measure	Time frame	Description
28-day mortality	28 days	mortality within 28 days after recruitment.

Countries

China

Outcome results